Dihidrexidina (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dihidrexidina" in Spanish language version.

refsWebsite

Global rank Spanish rank

9nih.gov

4^th place

7doi.org

2^nd place

2books.google.com

3^rd place

7^th place

1issn.org

57^th place

3^rd place

books.google.com

Gómez, José Luis Santos; Sánchez-Morla, Eva María; León, Ana Isabel Aparicio (27 de julio de 2016). Esquizofrenia: tratamiento de los síntomas negativos y cognitivos. Editorial Glosa, S.L. p. 126. ISBN 978-84-7429-644-0. Consultado el 11 de mayo de 2023.
Nuevas aportaciones en la búsqueda de antipsicóticos atípicos de estructura referible a butirofenona. Preparación de aminobutirofenonas de conformación restringida en las series del pirazol, isoxazol, oxazol y tiazol.. Univ Santiago de Compostela. p. 47-48. Consultado el 11 de mayo de 2023.

doi.org

dx.doi.org

Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, Mailman RB (1989). «Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist.». Eur J Pharmacol 166 (1): 111-113. PMID 2572425. doi:10.1016/0014-2999(89)90690-0.
Kilts, JD. (2002). «Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.». J Pharmacol Exp Ther 301 (3): 1179-89. PMID 12023553. doi:10.1124/jpet.301.3.1179.
Taylor JR, Lawrence MS, ((Redmond DE Jr)), Elsworth JD, Roth RH, Nichols DE, Mailman RB (1991). «Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys.». Eur J Pharmacol 199 (3): 389-391. PMID 1680717. doi:10.1016/0014-2999(91)90508-N.
Mailman RB, Nichols DE (1998). «Dopamine D1 receptor agonists as antiparkinson drugs.». Trends Pharmacol. Sci. 19 (7): 255-256. PMID 9703756. doi:10.1016/S0165-6147(98)01219-X.
Salmi, Peter; Isacson, Ruben; Kull, Björn (7 de junio de 2006). «Dihydrexidine - The First Full Dopamine D1 Receptor Agonist». CNS Drug Reviews 10 (3): 230-242. ISSN 1080-563X. doi:10.1111/j.1527-3458.2004.tb00024.x. Consultado el 11 de mayo de 2023.
George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB (2007). «A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.». Schizophr. Res. 93 (1–3): 42-50. PMID 17467956. doi:10.1016/j.schres.2007.03.011.
Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS (2007). «A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia.». Schizophr. Res. 94 (1–3): 332-341. PMID 17596915. doi:10.1016/j.schres.2007.03.033.

issn.org

portal.issn.org

Salmi, Peter; Isacson, Ruben; Kull, Björn (7 de junio de 2006). «Dihydrexidine - The First Full Dopamine D1 Receptor Agonist». CNS Drug Reviews 10 (3): 230-242. ISSN 1080-563X. doi:10.1111/j.1527-3458.2004.tb00024.x. Consultado el 11 de mayo de 2023.

nih.gov

ncbi.nlm.nih.gov

Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, Mailman RB (1989). «Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist.». Eur J Pharmacol 166 (1): 111-113. PMID 2572425. doi:10.1016/0014-2999(89)90690-0.
Mottola DM, Brewster WK, Cook LL, Nichols DE, Mailman RB (1992). «Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.». J Pharmacol Exp Ther 262 (1): 383-393. PMID 1352553.
Kilts, JD. (2002). «Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.». J Pharmacol Exp Ther 301 (3): 1179-89. PMID 12023553. doi:10.1124/jpet.301.3.1179.
((Darney KJ Jr)), Lewis MH, Brewster WK, Nichols DE, Mailman RB (1991). «Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist.». Neuropsychopharmacology 5 (3): 187-195. PMID 1684499.
Taylor JR, Lawrence MS, ((Redmond DE Jr)), Elsworth JD, Roth RH, Nichols DE, Mailman RB (1991). «Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys.». Eur J Pharmacol 199 (3): 389-391. PMID 1680717. doi:10.1016/0014-2999(91)90508-N.
Mailman RB, Nichols DE (1998). «Dopamine D1 receptor agonists as antiparkinson drugs.». Trends Pharmacol. Sci. 19 (7): 255-256. PMID 9703756. doi:10.1016/S0165-6147(98)01219-X.
Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, Chase TN (1998). «Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.». Clin. Neuropharmacol. 21 (6): 339-343. PMID 9844789.
George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB (2007). «A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.». Schizophr. Res. 93 (1–3): 42-50. PMID 17467956. doi:10.1016/j.schres.2007.03.011.
Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS (2007). «A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia.». Schizophr. Res. 94 (1–3): 332-341. PMID 17596915. doi:10.1016/j.schres.2007.03.033.